Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Zimmer Biomet Holdings's Debt-to-Equity or its related term are showing as below:
XSWX:ZBH'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.44 Med: 0.63 Max: 1.19
Current: 0.59
During the past 13 years, the highest Debt-to-Equity Ratio of Zimmer Biomet Holdings was 1.19. The lowest was 0.44. And the median was 0.63.
XSWX:ZBH's Debt-to-Equity is ranked worse than 73.76% of 705
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs XSWX:ZBH: 0.59
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Zimmer Biomet Holdings Debt-to-Equity Related Terms
Zimmer Biomet Holdings Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Zimmer Biomet Holdings's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:ZBH vs STE, PEN, GMED: Debt-to-Equity Comparison
For the Medical Devices subindustry, Zimmer Biomet Holdings's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zimmer Biomet Holdings Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Zimmer Biomet Holdings's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Zimmer Biomet Holdings's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zimmer Biomet Holdings (XSWX:ZBH) has a Debt-to-Equity of 0.59 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Zimmer Biomet Holdings and its competitors. This is near median its historical median of 0.63. Over the past decade, Zimmer Biomet Holdings' Debt-to-Equity has ranged from 0.44 to 1.19. According to the industry distribution chart, Zimmer Biomet Holdings ranks #520 out of 705 companies in the Medical Devices & Instruments industry, placing it in the top 73.8%.
Is Zimmer Biomet Holdings' Debt-to-Equity too high?
Zimmer Biomet Holdings' current Debt-to-Equity of 0.59 is near median its 10-year median of 0.63. Over the past 10 years, this metric has ranged from a low of 0.44 to a high of 1.19. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. Zimmer Biomet Holdings' value of 0.59 is 156.5% above this industry median. Based on the distribution chart, Zimmer Biomet Holdings ranks #520 out of 705 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Zimmer Biomet Holdings has a GF Score™ of 76/100, reflecting its overall financial health beyond just this single metric.
How does Zimmer Biomet Holdings' Debt-to-Equity compare to STE and PEN?
According to the Medical Devices & Instruments industry distribution chart, Zimmer Biomet Holdings ranks #520 out of 705 companies for Debt-to-Equity. This places Zimmer Biomet Holdings in the lower half of its industry. The industry median Debt-to-Equity is 0.23. Zimmer Biomet Holdings' value of 0.59 is 156.5% above this benchmark. Historically, Zimmer Biomet Holdings' own Debt-to-Equity has ranged from 0.44 to 1.19 over the past decade. While the company's 10-year median is 0.63 vs. the industry median of 0.23, Zimmer Biomet Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 705 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zimmer Biomet Holdings's current Debt-to-Equity of 0.59 is 156.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Zimmer Biomet Holdings and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zimmer Biomet Holdings's current Debt-to-Equity is 0.59, which is near median its own 10-year median of 0.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zimmer Biomet Holdings stock overvalued right now?
Zimmer Biomet Holdings (XSWX:ZBH) has a current Debt-to-Equity of 0.59. The stock's GF Value™ is CHF103.81, compared to a current price of CHF75.00 — trading 27.8% below its estimated fair value. The current Debt-to-Equity is 0.59, which is near median its 10-year median of 0.63 and 156.5% above the Medical Devices & Instruments industry median of 0.23. Zimmer Biomet Holdings' overall GF Score™ is 76/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Zimmer Biomet Holdings (XSWX:ZBH), the current Debt-to-Equity is 0.59 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zimmer Biomet Holdings (XSWX:ZBH) Overvalued in 2026?
Based on GuruFocus' analysis, Zimmer Biomet Holdings stock appears to be undervalued.
The current stock price of CHF75.00 is trading 27.8% below its estimated GF Value™ of CHF103.81.
Key valuation signals for XSWX:ZBH:
Debt-to-Equity: 0.59 (near median its 10-year median of 0.63)
GF Value™: CHF103.81 vs. price of CHF75.00 (27.8% below fair value)
Industry Position: 156.5% above the Medical Devices & Instruments median (#520 of 705)
No single metric tells the full story. See the XSWX:ZBH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
76GF Score
Get the complete analysis for XSWX:ZBH
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:ZBH has been successfully added to your 
